Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00223509 · ClinicalTrials.gov registry record · Phase 4

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

A Phase 4 study of Bipolar Disorder, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 4
Development phase
28
Enrollment target
2
Study locations

NCT00223509 is a Phase 4 study of Bipolar Disorder that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 28 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00223509, a Phase 4 study of Bipolar Disorder, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 4
Development phase
28 participants
Enrollment target
2
Study locations

Study Summary

* To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder. * To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed state of bipolar disorder

Conditions Studied

Interventions

  • DRUG Lamotrigine

Study Locations (2)

Texas

  • Univ of Texas Health Science Center at San Antonio - San Antonio
  • University of Texas Health Science Center at San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2005-08
Est. Completion 2007-11
Phase Phase 4

What the Registry Record Tells You About NCT00223509

The ClinicalTrials.gov registry entry for NCT00223509 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (92% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Lamotrigine is the first listed.

NCT00223509 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00223509 about?

NCT00223509 is a clinical study titled "Lamictal As Add on Treatment in Mixed States of Bipolar Disorder". * To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the acute treatment of patients in a mixed state of bipolar disorder. * To evaluate the efficacy and of a combination of LAM+existing regimen of mood stabilizers in the maintenance treatment of patients with mixed st...

What is the current status of trial NCT00223509?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2005-08. Estimated completion is 2007-11.

What conditions does trial NCT00223509 study?

This clinical trial studies the following conditions: Bipolar Disorder.

What interventions are being tested in trial NCT00223509?

The interventions under investigation include: Lamotrigine (DRUG).

Who is sponsoring clinical trial NCT00223509?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00223509 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.